Search research articles
Contact Us
Filters
Showing results (581-590 of 755) with videos related to
Page
of 76
Sort By:
Rheumatology and Therapy
|
January 5, 2024
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, et al.
Arthritis Care & Research
|
February 7, 2018
Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
Rina S Fox, Linda Kwakkenbos, Marie-Eve Carrier, et al.
The Journal of Rheumatology
|
October 6, 2005
Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update
Marissa N D Lassere, Kent R Johnson, Maarten Boers, et al.
Rheumatology (Oxford, England)
|
January 8, 2008
Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel
D E Furst, R J Halbert, C O Bingham, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 11, 2016
Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium
Elizabeth R Volkmann, Yu-Ling Chang, Nashla Barroso, et al.
Arthritis Research & Therapy
|
July 30, 2025
The diagnostic utility of lung ultrasound in the assessment of interstitial lung disease associated with rheumatoid arthritis
Shaoyu Zheng, Zexuan Zhou, Guangzhou Du, et al.
Clinical and Experimental Rheumatology
|
October 3, 2024
Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines
Weijin Zhang, Guohai Huang, Shaoyu Zheng, et al.
Rheumatology (Oxford, England)
|
August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards
Dinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
Annals of the Rheumatic Diseases
|
October 14, 2022
Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis
Julia Z Adamska, Amin Zia, Michelle S Bloom, et al.
The Lancet. Respiratory Medicine
|
September 1, 2020
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
Page
of 76
Search research articles
Search
Showing results (581-590 of 755) with videos related to
Sort By:
Page
of 76
Rheumatology and Therapy
|
January 5, 2024
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, et al.
Arthritis Care & Research
|
February 7, 2018
Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study
Rina S Fox, Linda Kwakkenbos, Marie-Eve Carrier, et al.
The Journal of Rheumatology
|
October 6, 2005
Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update
Marissa N D Lassere, Kent R Johnson, Maarten Boers, et al.
Rheumatology (Oxford, England)
|
January 8, 2008
Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel
D E Furst, R J Halbert, C O Bingham, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 11, 2016
Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium
Elizabeth R Volkmann, Yu-Ling Chang, Nashla Barroso, et al.
Arthritis Research & Therapy
|
July 30, 2025
The diagnostic utility of lung ultrasound in the assessment of interstitial lung disease associated with rheumatoid arthritis
Shaoyu Zheng, Zexuan Zhou, Guangzhou Du, et al.
Clinical and Experimental Rheumatology
|
October 3, 2024
Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines
Weijin Zhang, Guohai Huang, Shaoyu Zheng, et al.
Rheumatology (Oxford, England)
|
August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards
Dinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
Annals of the Rheumatic Diseases
|
October 14, 2022
Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis
Julia Z Adamska, Amin Zia, Michelle S Bloom, et al.
The Lancet. Respiratory Medicine
|
September 1, 2020
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
Page
of 76